Exhibit 99.1

SOCIETY PASS INCORPORATED

CONDENSED CONSOLIDATED BALANCE SHEETS

(Currency expressed in United States Dollars (“US$”))

		June 30, 2025				August 15, 2025
		(Unaudited)				(Proforma)(1)
ASSETS
Current assets:
Cash and cash equivalents		$	8,218,805			$	21,009,098
Restricted cash			50,000				50,000
Accounts receivable, net			1,064,164				708,315
Inventories			127,843				127,843
Contract assets			327,267				327,267
Deposits, prepayments and other receivables			12,796,555				6,533,361
Total current assets			22,584,634				28,755,884
Non-current assets:
Intangible assets, net			5,311,177				5,311,177
Goodwill			81,849				81,849
Plant and equipment, net			347,106				347,106
Right of use assets, net			809,329				809,329
Deferred tax assets			58,350				58,350
Total non-current assets			6,607,811				6,607,811
TOTAL ASSETS		$	29,192,445			$	35,363,695
LIABILITIES AND SHAREHOLDERS’ DEFICIT
Current liabilities:
Accounts payables		$	9,581,836			$	2,821,419
Contract liabilities			951,228				951,228
Accrued liabilities and other payables			15,492,850				15,492,850
Due to related parties			12,739				12,739
Operating lease liabilities			432,842				432,842
Loan			24,270				24,270
Total current liabilities			26,495,765				19,735,348
Non-current liabilities
Operating lease liabilities			377,776				377,776
Deferred tax liabilities			69,000				69,000
Total non-current liabilities			446,776				446,776
TOTAL LIABILITIES			26,942,541				20,182,124
COMMITMENTS AND CONTINGENCIES
Convertible preferred shares; $0.0001 par value, 5,000,000 shares authorized, 4,766,500 and 4,766,500 shares undesignated as of March 31, 2025 and December 31, 2024, respectively
Series A shares: 10,000 shares designated; 0 and 0 Series A shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively			—				—
Series B shares: 10,000 shares designated; 0 and 0 Series B shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively			—				—
Series B-1 shares: 15,000 shares designated; 0 and 0 Series B-1 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively			—				—
Series C shares: 15,000 shares designated; 0 and 0 Series C shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively, net of issuance cost			—				—
Series C-1 shares: 30,000 shares designated; 0 and 0 Series C-1 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively, net of issuance cost			—				—
SHAREHOLDERS’ EQUITY (DEFICIT) SURPLUS
Series X Super Voting Preferred Stock, $0.0001 par value, 153,500 shares designated; 153,500 and 153,500 Series X shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively			15				15
Common shares; $0.0001 par value, 50,000,000 shares authorized; 5,011,061 and 5,311,061 shares issued and outstanding as of May 31, 2025 and June 30, 2025, respectively			531				536
Subscription receivable			(381,111	)			(381,111	)
Additional paid-in capital			114,698,365				128,248,848
Less: Preferred stock held in treasury, at cost; 150,000 and 150,000 shares at May 31, 2025 and June 30, 2025, respectively			(15	)			(15	)
Less: Common shares held in treasury, at cost; 51,902 and 51,902 shares May 31, 2025 and June 30,2025, respectively			—				—
Accumulated other comprehensive loss			(380,449	)			(380,449	)
Accumulated deficit			(111,488,907	)			(112,091,618	)
Total (deficit) surplus attributable to Society Pass Incorporated			2,448,429				15,396,206
Non-controlling interest			(198,525	)			(214,635	)
TOTAL SHAREHOLDERS’ EQUITY (DEFICIT) SURPLUS			2,249,904				15,181,571
TOTAL LIABILITIES AND EQUITY		$	29,192,445			$	35,363,695

(1) Proforma as adjusted additional paid in capital reflects the net proceeds we expect to receive, after deducting underwriting fee, underwriter expense allowance and other expenses from the initial public offering (the “IPO”) of NusaTrip Incorporated, a subsidiary of the Company (“NusaTrip”). We received net proceeds of approximately $13,500,000 (gross offering proceeds of $15,000,000, less underwriting discounts of $1,050,000, non-accountable expense of 150,000 and offering expenses of $300,000, of which $263,194 have paid) from the IPO. The shares of common stock reflect the issuance and sale of 3,750,000 shares of common stock of NusaTrip at an initial public offering price of $4.00 per share after deducting underwriting discounts, underwriter expense allowance and other expenses.